6855 — Ascentage Pharma International Balance Sheet
0.000.00%
- HK$16.93bn
- HK$17.37bn
- CNY980.65m
Annual balance sheet for Ascentage Pharma International, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,024 | 1,707 | 1,476 | 1,069 | 1,237 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 13.4 | 76.5 | 61.5 | 164 | 99.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,079 | 1,885 | 1,636 | 1,344 | 1,474 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 477 | 844 | 649 | 957 | 906 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 1,731 | 2,940 | 2,830 | 2,500 | 2,618 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 276 | 361 | 881 | 934 | 1,167 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 884 | 1,705 | 2,422 | 2,440 | 2,354 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 847 | 1,235 | 409 | 60.4 | 264 |
Total Liabilities & Shareholders' Equity | 1,731 | 2,940 | 2,830 | 2,500 | 2,618 |
Total Common Shares Outstanding |